MedImmune Inc., of Gaithersburg, a biotechnology company focused on developing and manufacturing products to combat infectious disease, autoimmune disease and cancer, announced that it has begun shipping FluMist Quadrivalent to influenza distributors across the United States for the 2013-2014 influenza season.
This marks the first shipments of FluMist Quadrivalent, the first and only nasal-spray quadrivalent flu vaccine approved by the Food and Drug Administration to help protect against four influenza strains that may circulate in the coming flu season.
Earlier versions of FluMist were trivalent, that is, they helped fight three strains of flu.
FluMist Quadrivalent is approved for use by individuals and families ages 2 to 49 years old.
The 2013-2014 influenza season is the first time that quadrivalent influenza vaccines will be available in the United States.